Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients with Hypercholesterolemia – Meta-Analysis of 35 Randomized Controlled Trials
The authors from several American institutions examined the efficacy and safety of two proprotein convertase subtilisin/kexin type 9 (PCSK9i) inhibitors, alirocumab and evolocumab, in their work. They conducted a systematic meta-analysis of randomized controlled clinical trials comparing the administration of these two PCSK9i with standard treatment.
Analyzed Studies
The meta-analysis included 35 studies involving a total of 45,539 patients. The average age of participants was 61.0 ± 2.8 years, and their average initial LDL cholesterol level was 2.74 ± 0.57 mmol/l. The average follow-up period was 85.5 weeks.
Findings
Compared to patients who did not use PCSK9i, participants treated with PCSK9i showed a lower risk of myocardial infarction (2.3% with PCSK9i vs. 3.6% without PCSK9i; odds ratio [OR] 0.72; 95% confidence interval [CI] 0.64–0.81; p < 0.001), stroke (1.0% with PCSK9i vs. 1.4% without PCSK9i; OR 0.80; 95% CI 0.67–0.96; p = 0.02), and coronary revascularization (4.2% with PCSK9i vs. 5.8% without PCSK9i; OR 0.78; 95% CI 0.71–0.86; p < 0.001).
No significant difference was found in all-cause mortality (OR 0.71; 95% CI 0.47–1.09; p = 0.12) or cardiovascular mortality (OR 1.01; 95% CI 0.85–1.19; p = 0.95). Conversely, a significant association was found between higher initial LDL-c levels and the benefit from PCSK9i treatment in terms of all-cause mortality (p = 0.038).
No significant difference was observed between the PCSK9i-treated and untreated groups regarding neurocognitive adverse events (OR 1.12; 95% CI 0.88–1.42; p = 0.37), incidence of myalgia (OR 0.95; 95% CI 0.75–1.20; p = 0.65), development or worsening of pre-existing diabetes mellitus (OR 1.05; 95% CI 0.95–1.17; p = 0.32), or elevation of creatine kinase (OR 0.84; 95% CI 0.70–1.01; p = 0.06) or hepatic aminotransferases (OR 0.96; 95% CI 0.82–1.12; p = 0.61).
Conclusion
Treatment with PCSK9 inhibitors is well tolerated and improves cardiovascular outcomes. Although no benefit in overall or cardiovascular mortality was observed in this meta-analysis, such a benefit may be achievable in patients with higher baseline LDL cholesterol levels.
(epa)
Source: Karatasakis A., Danek B. A., Karacsonyi J. et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc 2017; 6 (12): e006910, doi: 10.1161/JAHA.117.006910.
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
